BYSI News and Press, BeyondSpring Inc. From 12/01/21

BeyondSpring Pharmaceuticals (NASDAQ:BYSI) announced that the FDA has issued a Complete Response Letter (CRL) for its New Drug Application (NDA) seeking the approval of a combination regimen containing plinabulin for chemotherapy-induced neutropenia (CIN). The company had sought regulatory ap...

NEW YORK, Dec. 01, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced it has received a Complete Response Lette...

Clinical stage biopharma companies BeyondSpring (NASDAQ:BYSI) and CTI BioPharma (NASDAQ:CTIC) have gained ~4.9% and ~4.5% in the pre-market, respectively on below-average volume as investors await the FDA decision on two of their product candidates. BeyondSpring (BYSI) has Nov. 30 a...

iSpecimen (NASDAQ:ISPC) +70% COVID-19 vaccine stocks surge on worries over new variant Allied Healthcare Products (NASDAQ:AHPI) +68%. Alpha Pro Tech (NYSE:APT) +24% Zoom Video and Peloton take off as new COVID variant revives stay-at-home trade Valneva SE (NASDAQ:VALN) +18...

NEW YORK, Nov. 24, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will participate in a Fireside Chat and h...

BeyondSpring is a clinical stage biopharma focused on immuno-oncology cancer therapies. CEO Dr. Lan Huang, a structural biologist by training, discusses potential for Plinabulin, industry trends and 2022 outlook. Why small molecule therapy, the bread and butter of cancer treatment...

Today, we look back in on a small oncology company called BeyondSpring for the first time since early this year. The stock quadrupled in August on good trial results but has fallen back 40% since then on some doubts around the data. Temporary setback or beginning of a larger move ...

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, today announced that management will present at and host one-on-one inves...

NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a clinical stage biopharmaceutical company focused on the development of innovative cancer therapeutics, today announced the appointmen...

If you're looking for stocks that can make big moves on a relatively predictable timeline, the biotechnology space has you covered. Hardly a day goes by where you don't see at least one stock from this industry rocket higher, or crash and burn. Right now, investors are waiting for n...